Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
Portfolio Pulse from
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the addition of new clinical sites at Harvard and Johns Hopkins for its Phase III clinical trial, FLAMINGO-01, which evaluates GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences.
January 23, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Greenwich LifeSciences has expanded its Phase III trial FLAMINGO-01 to include new clinical sites at Harvard and Johns Hopkins, potentially accelerating the development of GLSI-100, an immunotherapy for breast cancer.
The addition of prestigious institutions like Harvard and Johns Hopkins to the FLAMINGO-01 trial could enhance the credibility and progress of the study, potentially leading to positive outcomes for GLSI-100. This development is likely to be viewed positively by investors, as it may accelerate the path to market for the drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100